Skip to content

Drug interactions

Cobimetinib + Netupitant-palonosetron

Severity: Major

Cobimetinib and Netupitant-palonosetron: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Netupitant inhibits CYP3A4 and can increase cobimetinib exposure. This may increase toxicities such as hemorrhage, rhabdomyolysis, retinopathy and liver injury.

What this interaction means in plain words

Cobimetinib and Netupitant-palonosetron can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Cobimetinib belongs to Oncology; Netupitant-palonosetron belongs to Gastrointestinal Tract.

Evidence level: Moderate

Why it happens

CYP3A4 inhibition by netupitant reduces cobimetinib clearance.

What to do

Prefer an antiemetic that does not inhibit CYP3A4. If short-term use is unavoidable, reduce cobimetinib to the labeled dose for moderate inhibitors and monitor for toxicity.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Cobimetinib and Netupitant-palonosetron, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Cobimetinib with Netupitant-palonosetron?

MediHelp rates the interaction as major. Cobimetinib and Netupitant-palonosetron can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Netupitant inhibits CYP3A4 and can increase cobimetinib exposure. This may increase toxicities such as hemorrhage, rhabdomyolysis, retinopathy and liver injury.

How serious is the interaction between Cobimetinib and Netupitant-palonosetron?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer an antiemetic that does not inhibit CYP3A4. If short-term use is unavoidable, reduce cobimetinib to the labeled dose for moderate inhibitors and monitor for toxicity.

What other medicines interact with Netupitant-palonosetron?

MediHelp also lists interactions of Netupitant-palonosetron with, for example, Apomorphine, Flibanserin, Apalutamide. The full list is on the Netupitant-palonosetron page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in